Knee osteoarthritis
Conditions
Interventions
We will use a database of patients who participated in three studies that had the same inclusion and exclusion criteria and in which the procedure was performed by the same rheumatologist.
Patients wi
Sponsors
Universidade Federal de São Paulo
Universidade Federal de São Paulo
Eligibility
Age
38 Years to 80 Years
Inclusion criteria
Inclusion criteria: Patients with primary OA on their knees according to the classification criteria of the American College of Rheumatology; Radiological classification of KL I, II and III; Age between 40 and 80 years; Both genders; Duration of knee pain greater than 6 months; Visual Analogue Scale (0-10 cm VAS) of pain at rest between 4 and 8 cm; Use of anti-arthritic medication stable for 3 months; Use of systemic corticosteroids stable for 1 month; Without intra-articular injection with corticosteroids in the studied knee or in any joint in the last 3 months; Read, accept and sign the Informed Consent Form (ICF) of the three prospective studies whose data already tabulated will be used in the present study.
Exclusion criteria
Exclusion criteria: Decompensated Melitus Diabetes and Hypertension; secondary OA; Trauma in the studied joint; Past treatment with instrumentation on the knee studied; Performing intra-articular injection in any joint in the last 3 months; Any changes in the treatment of the knee to be studied in the last 3 months (medication, rehabilitation, use of walking aid, acupuncture, orthosis, insole); Deformity in the studied knee that disrupts the gait; Severe clotting disorder; Suspected bacterial infection of any kind; Be a carrier of psychotic diseases; Pregnant; Present severe deformity in the knee to be studied; Have mobility difficulties or use of wheelchairs; Any skin lesion on the knee to be infiltrated; Cardiovascular or respiratory disease that interfered with functional status; Uncontrolled fibromyalgia.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean difference in knee pain on movement, measured by the visual analogue pain scale (0-10 cm), at the beginning of the study, middle (4 weeks) and end of the study (12 weeks) | — |
Secondary
| Measure | Time frame |
|---|---|
| Mean difference in knee pain at rest, measured by the visual analogue pain scale (0-10 cm), at the beginning of the study, middle (4 weeks) and end of the study (12 weeks);Mean difference in range of motion for knee flexion and extension, measured using a goniometer, at the beginning of the study, middle (4 weeks) and end of the study (12 weeks);Mean difference in function, measured by the WOMAC functional questionnaire at the beginning of the study, middle (4 weeks) and end of the study (12 weeks);Mean difference in quality of life, measured by the generic SF-36 questionnaire at the beginning of the study, middle (4 weeks) and end of the study (12 weeks);Mean difference in the overall improvement of the patient after the procedure, measured using a likert scale at the beginning of the study, middle (4 weeks) and end of the study (12 weeks);Mean difference in function, measured by the timed to up and go (TUGT) test at the beginning of the study, middle (4 weeks) and end of the study (12 weeks) 12 weeks;Count of side effects related to intra-articular injection measured at the beginning of the study, middle (4 weeks) and end of the study (12 weeks);Count of daily painkillers needs measured at the beginning of the study, middle (4 weeks) and end of the study (12 weeks) | — |
Countries
Brazil
Contacts
Public ContactRita Furtado
Outcome results
None listed